Literature DB >> 30320088

Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings.

Chau M Pham1, Steven M Couch1, George J Harocopos1,2.   

Abstract

BACKGROUND/AIMS: Our study aims to better characterize the clinical and histopathologic features of eyes with extrascleral uveal melanoma associated with scleral melt following brachytherapy.
METHODS: A retrospective review was performed on patients who had undergone 125I (iodine-125) brachytherapy for uveal melanoma at our institution between 1992 and 2015. Patients with postradiation scleral necrosis who required enucleation were identified, and an analysis including a review of histopathology results was performed on those cases.
RESULTS: A total of 301 patients underwent plaque brachytherapy for uveal melanoma, of whom 31 required eventual enucleation. The histologic analysis showed extraocular extension through full-thickness scleral discontinuities in 6 cases. All but 1 (5 of 6) of these eyes exhibited either mitotic figures or Ki-67 positivity. Mitotic figures were noted in 4 specimens, including 3 eyes exhibiting mitoses within or adjacent to the extrascleral portion of the tumor. Two eyes exhibiting mitoses, as well as the case with Ki-67 positivity, also had clinical evidence of tumor regrowth.
CONCLUSION: We found evidence of mitotic activity at the area of scleral discontinuity in some eyes with and in some without clinical evidence of tumor regrowth. Protruding pigmented material in areas of scleral necrosis after plaque brachytherapy may represent actively proliferating tumors even without internal evidence of tumor regrowth.

Entities:  

Keywords:  125I brachytherapy; Choroidal melanoma; Histopathology; Plaque brachytherapy; Uveal melanoma

Year:  2017        PMID: 30320088      PMCID: PMC6167664          DOI: 10.1159/000477302

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  22 in total

1.  Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy.

Authors:  Milam A Brantley; Lori Worley; J William Harbour
Journal:  Am J Ophthalmol       Date:  2002-02       Impact factor: 5.258

2.  Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.

Authors:  K Gündüz; C L Shields; J A Shields; J Cater; J E Freire; L W Brady
Journal:  Arch Ophthalmol       Date:  1999-02

3.  Early-onset scleral necrosis after iodine I 125 plaque radiotherapy for ciliochoroidal melanoma.

Authors:  Z M Corrêa; J J Augsburger; J Freire; R C Eagle
Journal:  Arch Ophthalmol       Date:  1999-02

4.  Ocular complications after therapeutic irradiation.

Authors:  P A Macfaul; M A Bedford
Journal:  Br J Ophthalmol       Date:  1970-04       Impact factor: 4.638

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Ki-67 immunostaining in uveal melanoma. The effect of pre-enucleation radiotherapy.

Authors:  C M Mooy; P T de Jong; T H Van der Kwast; P G Mulder; M J Jager; D J Ruiter
Journal:  Ophthalmology       Date:  1990-10       Impact factor: 12.079

7.  Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.

Authors:  R Max Conway; Antony M Poothullil; Inder K Daftari; Vivian Weinberg; Juliet E Chung; Joan M O'Brien
Journal:  Arch Ophthalmol       Date:  2006-06

8.  Histopathology of uveal melanomas treated with charged particle radiation.

Authors:  J B Crawford; D H Char
Journal:  Ophthalmology       Date:  1987-06       Impact factor: 12.079

9.  Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients.

Authors:  Carol L Shields; Masood Naseripour; Jacqueline Cater; Jerry A Shields; Hakan Demirci; Asraf Youseff; Jorge Freire
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

10.  American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients.

Authors:  Carol L Shields; Swathi Kaliki; Minoru Furuta; Enzo Fulco; Carolina Alarcon; Jerry A Shields
Journal:  Ophthalmology       Date:  2013-05-09       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.